IDEXX Laboratories ( IDXX ) delivered a very strong quarter and exceeded expectations. With Cancer Dx and InVue , further growth is likely in the future, which is why I consider theMy primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for these companies to demonstrate a long- ...